Jaguar Health names new SVP of Growth Strategy
- ByInvesting.com
- •
Jaguar Health, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. It operates through two segments: human health and animal health. Human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. Its subsidiary includes Napo Pharmaceuticals, Inc., which focuses on developing and commercializing plant-based human pharmaceuticals.